Why the BARD1 (ASX:BD1) share price shot up 10% today

The BARD1 (ASX: BD1) share price is up today after the company signed an agreement that will help in type 3c diabetes diagnosis.

The BARD1 Life Sciences Limited (ASX: BD1) share price rocketed 9.71% on opening today after the company signed an agreement with the University of Liverpool.

The agreement is the first step towards licensing BARD1's blood test, which the company hopes will diagnose novel type 3c diabetes. So far, the test has shown promise in preliminary testing. The ability to diagnose type 3c diabetes and other technology BARD1 currently has in the works may help diagnose pancreatic cancer.

After peaking in early trade at $3.71, the BARD1 share price has since lost ground and is now swapping hands at $3.45, up 2.37% at the time of writing. 

Let's look closer at today's announcement from the medical diagnostic company.

A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech, and health companies.

Image source: Getty Images

New options agreement

The options agreement between BARD1 and the University of Liverpool will evaluate 2 novel protein biomarkers.  In preliminary testing, the protein biomarkers can accurately distinguish type 3c diabetes from type 2 diabetes.

The agreement will allow the company the option to licence the intellectual property and commercialise the blood test. In return, BARD1 will pay a non-material upfront options fee and cover any patient costs incurred by the University.

BARD1 states type 3c diabetes accounts for up to 10% of new diabetes diagnoses, but it is under-diagnosed and poorly managed.

What does this mean for fighting pancreatic cancer?

Diabetes is often linked to the pancreas, where insulin is produced. Those with diabetes either don't produce enough insulin or don't respond well to insulin, or a combination of both.

In BARD1's release, it stated around 10% of type 3c diabetes cases were caused by underlying pancreatic cancer. Thus, being quickly diagnosed specifically with type 3c diabetes can be of vital importance.

There is no test for pancreatic cancer, and it has a 5-year survival rate of just 10%.

One of the risk factors for pancreatic cancer, chronic pancreatitis, is the main causes of type 3c diabetes. Not to mention, a diagnosis of diabetes is another major risk factor for the cancer.

BARD1 is also investigating 2 novel approaches for screening pancreatic cancer using its technology to create a test for the cancer. 

Commentary from management

BARD1 CEO Dr Leearne Hinch commented on the technology's potential, saying:

Currently no screening test is available for pancreatic cancer and even if there was, it would not be practical or cost-effective to screen the average-risk general population.

BARD1's approach of developing a much-needed blood test for the detection of type 3c diabetes, which also provides a high-risk group for our screening test for pancreatic cancer, provides an ideal and clinically useful solution for both these global health problems.

BARD1 continues to deliver on its mission to develop non-invasive diagnostic tests that make a real difference to patient health outcomes in critical areas of unmet medical need including Type 3c diabetes and pancreatic cancer.

BARD1 Life Sciences share price snapshot

The BARD1 Life Sciences share price has had a ripper year on the ASX so far.

Currently, it's up a whopping 422% year-to-date. It's also up 360% over the last 12 months.

BARD1 has a market capitalisation of around $277 million, with approximately 80 million shares outstanding.  

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »